Abstract: The present invention is related to a method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue. Examples of re-epithelialization in which the invention is particularly suited include, but are not limited to, re-epithelialization of (a) skin following surgical wounds, (b) skin abrasions caused by mechanical trauma, caustic agents or burns, (c) cornea following cataract surgery or corneal transplants, (d) mucosal epithelium (respiratory, gastrointestinal, genitourinary, mammary, oral cavity, ocular tissue, liver and kidney) following infection, nonpathological etiologies or drug therapy, (e) skin following grafting and (f) renal tubule following acute tubular necrosis. Examples of re-endothelialization in which the invention is particularly suited include, but are not limited to, re-endothelialization (or regrowth of endothelium) in blood vessels following angioplasty, and the lysis of fibrin clots or lysis or mechanical disruption of thrombi in coronary arteries.

Abstract: Novel sweetening compound characterized in that it is N-?N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl!-L-hexahydrophenylalanine 1-methyl ester of formula: ##STR1## and its method of preparation characterized in that an aqueous/alcohol solution of pH 4.5-5 of aspartame and 3,3-dimethylbutyraldehyde at room temperature is treated with hydrogen at a pressure of 3 bars in the presence of a catalyst based on platinum such as platinum black and platinum oxide and in that the product formed is purified by precipitation and filtration after evaporation in vacuo of the alcohol part of the solvent.

Abstract: .beta.-Hydroxyamines and .beta.-hydroxycarbamates are synthesized from olefin substrates by means on a catalyzed asymmetric addition reaction. The addition reaction is catalyzed by osmium and is co-catalyzed by chiral ligands. The chiral ligands, in addition to being co-catalysts with the osmium, also serve to direct the addition reaction regioselectively and enantioselectively. Divalent ligands are preferred over monovalent ligands because of their enhance regio- and enantio-selectivity. Carbamates are employed as an oxidant nitrogen source for the production of .beta.-hydroxysulfonamides. Excellent yields and enantiomeric efficiencies are achieved with co-solvents containing a 50/50 (v/v) mixtures of water and organic solvent. The performance of the reaction is further enhanced by omitting the addition silver or mercurial salts conventionally employed in asymmetric aminohydroxylation additions to olefins performed in neat or substantially neat solvents. .beta.

Abstract: Y is O or S;R.sup.1 is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy;R.sup.2 is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkenyloxy, C.sub.2 -C.sub.4 alkynyl, C.sub.2 -C.sub.4 alkynyloxy, mono-, di- or tri-halomethyl, trifluoromethoxy, C.sub.2 -C.sub.4 alkylthio, C.sub.3 -C.sub.4 branched alkylthio, nitro, or cyano;R.sup.3 is hydrogen, halogen, methyl, mono-, di- or tri-halomethyl;R.sup.4 isa) C.sub.3 -C.sub.8 cycloalkyl substituted by one or more C.sub.1 -C.sub.4 alkyl, preferably one or two methyl;orb) ##STR2## wherein R.sup.6 and R.sup.7 are independently, hydrogen or linear or branched, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, or C.sub.2 -C.sub.4 alkynyl, and R.sup.8 is C.sub.3 -C.sub.8 cycloalkyl substituted by one or more C.sub.1 -C.sub.4 alkyl; andR.sup.5 is an acyclic or cyclic side chain as defined herein.These compounds are useful for inhibiting the growth or replication of retroviruses such as HIV.

Abstract: Method and apparatus are described for isolating natural therapeutic compositions from source materials. The method and apparatus isolate natural therapeutic compositions from waxes, fats, oils and other constituents of the source material with the use of supercritical, critical or near critical fluids.

Abstract: The present invention relates to disodium 4-chlorophenylthiomethylenebisphosphonate monohydrate.The invention further relates to the method of preparing this monohydrate.The invention further relates to the pharmaceutical compositions in which disodium tiludronate monohydrate is present as the active principle.

Abstract: N-(4-Bromo-2-fluorobenzyl)carbamates and a process for their preparationThe invention relates to N-(4-bromo-2-fluorobenzyl)carbamates of the formula (I), ##STR1## where R is (C.sub.1 -C.sub.12)alkyl, benzyl or phenyl, where the benzyl and phenyl radicals can also be substituted by (C.sub.1 -C.sub.3)alkyl or (C.sub.1 -C.sub.3)alkoxy, and to a process for preparing these compounds.

Abstract: Succinoylamino hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: The present invention provides a convenient, simple, safe and efficient one-pot method for the synthesis of a number of diarlyiodonium triflate salts which does not involve sulfuric acid and which eliminates the need for any counter-ion exchange processes.

Abstract: This invention concerns compounds of generic formula: ##STR1## or a pharmaceutically acceptable salt thereof, where the dotted line represents an optional bond,one of R.sup.1 and R.sup.5 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.7 -C.sub.16 aralkyl, --(CHR.sup.6).sub.n CHR.sup.7 CN, --(CHR.sup.6).sub.n CHR.sup.7 CONH.sub.2, --(CHR.sup.6).sub.n CHR.sup.7 COOR.sup.8, --(CHR.sup.6).sub.n CHR.sup.7 CH.sub.2 OH wherein n is 0 or 1, R.sup.6 and R.sup.7 independently represent hydrogen, C.sub.1 -C.sub.6 alkyl- or C.sub.7 -C.sub.16 aralkyl-, and R.sup.7 also represents hydroxy(C.sub.1 -C.sub.6)alkyl-, (C.sub.2 -C.sub.7)alkanoyloxy(C.sub.1 -C.sub.6)alkyl-, (C.sub.1 -C.sub.6 alkoxy)carbonyl- and R.sup.8 is hydrogen or C.sub.1 -C.sub.6 alkyl;the other of R.sup.1 and R.sup.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.7 -C.sub.16 aralkyl; R.sup.3 is C.sub.6 -C.sub.10 aryl or heteroaryl group optionally substituted by one or more substituents the same or differnet,R.sup.2 and R.sup.

Abstract: The invention relates to a process for the production of sulfuric acid semi-esters of general formula IRO--SO.sub.2 --OH (I),in whichR represents an organic radical, from hydroxy compounds of general formula IIR--OH (II),in whichR has the same meaning as in formula I, characterized in that the latter is reacted in an inert solvent with a disulfuric acid salt of general formula IIIO(SO.sub.2 OX).sub.2 (III),in whichX symbolizes an alkali metal atom.

Abstract: A hydroformylation process for the production of linear aldehydes of an olefin, with hydrogen and carbon monoxide in a solvent containing a catalyst having a platinum component, a bidentate diaryl phosphine component where the bridging group is ferrocenyl, and an acid promoter component.

Abstract: Oxalic acid diarylamides are described as useful monomers and comonomers in the polymerization of polycarbonates. The resin products resist degradation by ultra-violet light radiation. They can also be incorporated as comonomer or monomer in the polyester, polyester, polyether, polyethersulfone resins. They can also be used as UV stabilizers in the aforemetioned systems.

Abstract: Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.

Abstract: A process for the preparation of aromatic substituted carboxylic acids is disclosed. The process comprisesi) forming an aromatic-substituted acrylonitrile by dehydrating a cyanohydrin of the formula ##STR1## where Ar is C.sub.6 to C.sub.10 aryl unsubstituted or substituted with C.sub.1 to C.sub.6 linear or branched alkyl, C.sub.1 to C.sub.6 linear or branched alkoxy, halo, amino, amino mono- or disubstituted with C.sub.1 to C.sub.6 linear or branched alkyl or carboxylic acid or the alkyl esters thereof; and R is hydrogen or C.sub.1 to C.sub.6 linear or branched alkyl;ii) catalytically reducing the aromatic-substituted acrylonitrile when not more than 10% of the cyanohydrin is converted to said acrylonitrile to form a first reaction solution comprising an aromatic substituted aliphatic nitrile;iii) hydrolyzing the aromatic-substituted aliphatic nitrile.

Abstract: Process for the preparation of a fluorinated sulphonic acid compound by hydrolysis of a corresponding fluorinated sulphonyl fluoride in the presence of a tertiary amine, comprising steps of(a) recovering a mixture of a salt of the fluorinated sulphonic acid with the tertiary amine and an ammonium fluoride salt of the tertiary amine;(b) distilling off the tertiary ammonium fluoride salt and leaving a distillation remanence containing the salt of the fluorinated sulphonic acid with the tertiary amine; and(c) recovering the fluorinated sulphonic acid compound from the distillation remanence.

Abstract: Novel compounds useful as sequestrants as well as builders for detergent compositions and methods for their preparation are disclosed.

Abstract: The present invention provides novel hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these novel compounds for the inhibition of matrix metalloproteinases, such as stromelysin, and inhibit the production of tumor necrosis factor alpha, and for the treatment of arthritis and other related inflammatory diseases.

Abstract: Substituted azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 is R.sup.3 -substituted aryl;Ar.sup.2 is R.sup.4 -substituted aryl;Ar.sup.3 is R.sup.5 -substituted aryl;Y and Z are independently --CH.sub.2 --, --CH(lower alkyl)- or --C(dilower alkyl)-;A is --O--, --S--, --S(O)-- or --S(O).sub.2 --;R.sup.1 is --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6 R.sup.7 ; R.sup.2 is hydrogen, lower alkyl or aryl; or R.sup.1 and R.sub.2 together are .dbd.O;q is 1, 2 or 3; p is 0, 1, 2, 3 or 4;R.sup.5 is 1-3 substituents independently selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5 OR.sup.9, --O(CO)NR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.6 (CO)R.sup.7, --NR.sup.6 (CO)OR.sup.9, --NR.sup.6 (CO)NR.sup.7 R.sup.8, --NR.sup.6 SO.sub.2 -lower alkyl, --NR.sup.6 SO.sub.2 -aryl, --CONR.sup.6 R.sup.7, --COR.sup.6, --SO.sub.2 NR.sup.6 R.sup.7, S(O).sub.0-2 -alkyl, S(O).sub.0-2 -aryl, --O(CH.sub.2).

Abstract: The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and selected from H and alkyl; X is selected from alkylthio, arylthio, aryloxy, halogen and cyano; R.sup.3, R.sup.4 are the same or different and selected from halogen, methyl, fluoroalkyl, cyano and Z--R.sup.5 wherein Z is selected from CH.sub.n, NH.sub.m, O, S, SO.sub.2 and CO wherein n=1 or 2; m=0 or 1 and R.sup.5 is selected from alkyl, aryl and fluoroalkyl; or R.sup.3 and R.sup.4 together form a saturated or unsaturated ring system Y--V--Z wherein Y and Z, independently of each other, are as defined for Z above and V is selected from C.sub.1 -C.sub.3 alkylene or alkenylene, --N.dbd., --N.dbd.N-- and ##STR2## wherein R.sub.